Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age

M. Trkova, K. Prochazkova, V. Krutilkova, D. Sumerauer, Z. Sedlacek

. 2007 ; 110 (3) : 694-702.

Language English Country United States

Document type Comparative Study

BACKGROUND: A decrease in the age at cancer onset and increase in cancer incidence in successive generations in Li-Fraumeni syndrome (LFS) families with germline TP53 mutations have been previously described. In the current study a possible relation was analyzed between telomere length and cancer onset in TP53 mutation carriers. METHODS: Telomere length was measured using real-time quantitative polymerase chain reaction (PCR) in 20 carriers of germline TP53 mutations and in 83 unrelated healthy individuals. According to the age at blood sampling, patients and controls were divided into 2 age groups, children and adults. Telomere length was correlated to TP53 mutation status and telomere shortening in patients to the age at cancer onset. A t-test and linear regression were used to analyze the data. RESULTS: Compared with healthy controls, telomere length was significantly shorter both in the child (P = .001) and adult (P = .034) germline T53 mutation carriers. Although a statistically significant correlation between telomere shortening and the age at cancer onset was not observed, there was a trend of shorter telomeres in mutation carriers affected in childhood compared with those affected later in life. Neither cancer therapy nor sex differences were likely to affect the results. CONCLUSIONS: The findings suggest a possible link between the carriership of a germline TP53 mutation, telomere length, predisposition to early-onset cancer, and anticipation in LFS. (c) 2007 American Cancer Society.

References provided by Crossref.org

000      
03342naa 2200469 a 4500
001      
bmc10010416
003      
CZ-PrNML
005      
20240125152605.0
008      
100430s2007 xxu e eng||
009      
AR
024    __
$a 10.1002/cncr.22834 $2 doi
035    __
$a (PubMed)17567834
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Trková, Marie $7 xx0164107
245    10
$a Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age / $c M. Trkova, K. Prochazkova, V. Krutilkova, D. Sumerauer, Z. Sedlacek
314    __
$a Department of Biology and Medical Genetics, Charles University 2nd Medical School and University Hospital Motol, Prague, Czech Republic. marie.trkova@lfmotol.cuni.cz
520    9_
$a BACKGROUND: A decrease in the age at cancer onset and increase in cancer incidence in successive generations in Li-Fraumeni syndrome (LFS) families with germline TP53 mutations have been previously described. In the current study a possible relation was analyzed between telomere length and cancer onset in TP53 mutation carriers. METHODS: Telomere length was measured using real-time quantitative polymerase chain reaction (PCR) in 20 carriers of germline TP53 mutations and in 83 unrelated healthy individuals. According to the age at blood sampling, patients and controls were divided into 2 age groups, children and adults. Telomere length was correlated to TP53 mutation status and telomere shortening in patients to the age at cancer onset. A t-test and linear regression were used to analyze the data. RESULTS: Compared with healthy controls, telomere length was significantly shorter both in the child (P = .001) and adult (P = .034) germline T53 mutation carriers. Although a statistically significant correlation between telomere shortening and the age at cancer onset was not observed, there was a trend of shorter telomeres in mutation carriers affected in childhood compared with those affected later in life. Neither cancer therapy nor sex differences were likely to affect the results. CONCLUSIONS: The findings suggest a possible link between the carriership of a germline TP53 mutation, telomere length, predisposition to early-onset cancer, and anticipation in LFS. (c) 2007 American Cancer Society.
650    _2
$a dospělí $7 D000328
650    _2
$a věk při počátku nemoci $7 D017668
650    _2
$a dítě $7 D002648
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a zárodečné mutace $x genetika $7 D018095
650    _2
$a detekce genetických nosičů $7 D006580
650    _2
$a lidé $7 D006801
650    _2
$a Liův-Fraumeniho syndrom $x genetika $x krev $7 D016864
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nádory $x genetika $x krev $7 D009369
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a telomery $x fyziologie $7 D016615
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
650    _2
$a financování organizované $7 D005381
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Procházková, Kamila. $7 _AN051942
700    1_
$a Krutílková, Věra $7 xx0156528
700    1_
$a Sumerauer, David $7 xx0105538
700    1_
$a Sedláček, Zdeněk, $d 1960- $7 skuk0005184
773    0_
$t Cancer $w MED00001031 $g Roč. 110, č. 3 (2007), s. 694-702 $x 0008-543X
910    __
$a ABA008 $b x $y 8 $z 0
990    __
$a 20100503140203 $b ABA008
991    __
$a 20240125152559 $b ABA008
999    __
$a ok $b bmc $g 724097 $s 587231
BAS    __
$a 3
BMC    __
$a 2007 $b 110 $c 3 $d 694-702 $i 0008-543X $m Cancer $n Cancer $x MED00001031
LZP    __
$a 2010-B2/dkme

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...